MENU

Can Ionis Pharmaceuticals (IONS) Stock Reach $84?

a developer of antisense drugs

Industry: #Biotechnology
A.I.Advisor
published price charts
A.I.Advisor
Nov 09, 2026

Can Ionis Pharmaceuticals (IONS) Stock Reach $84?

Ionis Pharmaceuticals, Inc. (IONS) is a commercial-stage biotechnology company that develops RNA-targeted, antisense-based medicines. The question on investors' minds after a steep selloff is whether the shares can climb back toward the $84 level, a figure that sits roughly 171% above the latest close of $31.04. This article examines what that target represents, what could drive a recovery, and the obstacles in the way.

Key Takeaways

  • The central target of $84 is the arithmetic mean of roughly 25 analyst price targets, averaging about $84.13 per share, as compiled by S&P Global and mirrored by Yahoo Finance.
  • At a recent close of $31.04, reaching $84 would require a rise of roughly 171%, a very large move that is far from a near-term inevitability.
  • Individual targets span a wide range, from about $54 (Raymond James, set Nov. 9, 2026) to $105 and higher, reflecting deep disagreement about the commercial launch and pipeline.
  • The strongest supports are a growing DAWNZERA franchise, a diversified late-stage pipeline, and a healthy cash position of roughly $2.1 billion.
  • The biggest risks are a slower-than-expected launch of TRYNGOLZA and partnered pipeline setbacks, including Novartis largely abandoning the pelacarsen program.
  • For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • You can also explore Trending AI Robots to see how AI-driven tools track changing market conditions.

Analyst Price Targets and Consensus View

The $84 stock price target reflects a broad, current analyst universe rather than any single firm's opinion. Roughly 25 analyst price targets average about $84.13, a figure independently reported by both S&P Global via StockAnalysis and Yahoo Finance. The dispersion is unusually wide, with individual targets ranging from approximately $54 to $105 or higher, which signals genuine uncertainty about Ionis's near-term trajectory.

Sentiment remains nominally bullish, with a consensus "Buy" rating and no Sell ratings in recent tallies, yet the reasoning behind individual targets differs sharply. Bullish analysts emphasize the validated antisense platform, DAWNZERA's steady growth in hereditary angioedema, and multi-billion-dollar peak-sales potential for TRYNGOLZA. More cautious analysts point to persistent losses, cash burn, and launch execution risk.

Recent actions illustrate the divide. On Nov. 9, 2026, H.C. Wainwright reiterated a $100 target while Piper Sandler held $87, whereas Raymond James set a target of $54 the same day. BMO Capital upgraded the shares with a $66 target on Nov. 2, and Citi ($100) and Canaccord Genuity ($85) maintained Buy ratings in late October. Analysts differ on how quickly TRYNGOLZA can convert physician enthusiasm into prescriptions.

Current Market Position and Path Toward the Target

Ionis shares closed at $31.04 on Nov. 9, 2026, down roughly 21% in a single session and trading near a 19-month low. Reaching $84 implies a gain of approximately 171%, which is a very large move and would require a fundamental re-rating rather than a modest rebound.

The selloff followed third-quarter results that were otherwise solid: revenue of $243 million beat expectations of about $178 million, and a loss of $0.66 per share was narrower than the roughly $1.01 loss analysts had projected. The problem was guidance. Management cut its full-year 2026 sales outlook for TRYNGOLZA to about $50 million from $100–$110 million, citing a "more gradual-than-anticipated" launch ramp. Separately, collaboration partner Novartis said it is largely abandoning development of pelacarsen, an experimental cardiovascular drug. Ionis nonetheless reaffirmed total 2026 revenue guidance of $875–$900 million.

What Could Support a Move Toward the Target

The bull case rests on commercial diversification and pipeline depth. DAWNZERA is growing steadily, with $37 million in third-quarter revenue, and the company reaffirmed its $110–$120 million full-year target. The launch of ZANVASTRO, a treatment for Alexander disease, has begun, and HIBSAGO has gained U.S. and Japanese approvals. Ionis also points to positive Phase 3 data for sefaxersen and ulefnersen.

Financially, the company held roughly $2.1 billion in cash at mid-year and reiterated a path toward cash-flow breakeven by 2028. A large addressable patient population for TRYNGOLZA in severe hypertriglyceridemia (sHTG) keeps peak-sales expectations elevated among bulls, even if the ramp is slower than hoped.

What Could Prevent the Target From Being Reached

The primary obstacle is execution. TRYNGOLZA generated only $9 million in third-quarter sales, well below estimates of roughly $25–$27 million, and only about 24% of prescribers have written more than one prescription. A slower launch directly pressures revenue assumptions embedded in higher price targets.

Clinical and partner risk is also material. Beyond the pelacarsen setback, a July 2026 Phase 3 miss for eplontersen (the CARDIO-TTRansform study) already weighed on sentiment. Ionis also remains unprofitable, with a projected 2026 operating loss of $425–$475 million and elevated financial leverage, which limits flexibility while losses persist.

Technical Levels and Market Structure

Ionis traded within a 52-week range of roughly $42 to $87 before the November breakdown, so the stock has now sliced below its prior support level and turned that zone into overhead resistance. Any recovery would first need to reclaim the $42–$45 area, with the psychological $30 level acting as near-term support below the current price. The long-term trend structure is clearly damaged until the shares can stabilize and build a base above former support.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Key items to watch include quarterly TRYNGOLZA prescription trends and any updates to peak-sales assumptions, DAWNZERA and ZANVASTRO launch progress, European approval decisions, and the outcome of late-stage pipeline readouts. Changes in analyst targets, cash-burn trajectory, and any restructuring of the Novartis collaboration on pelacarsen are also important signposts.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like IONS, these signals can help traders spot changing trends, monitor positions, and surface opportunities more efficiently than manual review. Explore the AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.

Final Assessment

The $84 average analyst price target for Ionis Pharmaceuticals (IONS) sits roughly 171% above the latest close of $31.04, making it a very large required move. It is not a guarantee but an average of widely dispersed individual forecasts, from about $54 to $105, reflecting genuine disagreement over launch execution and pipeline value. The bull case leans on a diversified commercial portfolio, a validated platform, and a strong cash position; the bear case rests on a faltering TRYNGOLZA launch, recent clinical disappointments, and continued losses. Whether the shares can reach $84 will likely hinge on whether TRYNGOLZA prescriptions accelerate and pipeline catalysts convert into durable revenue growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

IONS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ARWR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
-2.35%
ARWR - IONS
50%
Loosely correlated
-5.22%
ZURA - IONS
49%
Loosely correlated
-2.30%
ABEO - IONS
46%
Loosely correlated
-1.22%
AXON - IONS
43%
Loosely correlated
-5.16%
PRME - IONS
41%
Loosely correlated
-7.55%
More
Can Ionis Pharmaceuticals (IONS) Stock Reach $84?